Terapeutilised antikehad

Kirjandusallikad

Originaalartiklid:

  1. Köhler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256: 495-7.
  2. Morrison SL, Johnson MJ, Herzenberg LA, Oi VT (1984). Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci USA 81: 6851-5.
  3. Jones PT, Dear PH, Foote J, Neuberger MS, Winter G (1986). Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321: 522–525.
  4. McCafferty J, Griffiths AD, Winter G, Chiswell DJ (1990) Phage antibodies: filamentous phage displaying antibody variable domains. Nature 348: 552-4.
  5. Boder ET, Wittrup KD (1997) Yeast surface display for screening combinatorial polypeptide libraries. Nat Biotechnol 15: 553-7.
  6. Hanes J, Plückthun A (1997) In vitro selection and evolution of functional proteins by using ribosome display. Proc Natl Acad Sci USA 94: 4937-42.

Ülevaateartiklid:

  1. Hoogenboom HR (2005) Selecting and screening recombinant antibody libraries. Nat Biotechnol 23: 1105-16. http://www.ncbi.nlm.nih.gov/pubmed/16151404
  2. Lonberg N (2005) Human antibodies from transgenic animals. Nat Biotechnol. 23(9): 1117-25. http://www.ncbi.nlm.nih.gov/pubmed/16151405
  3. Carter PJ (2006). Potent antibody therapeutics by design. Nat Rev Immunol 6 (5): 343-57. http://www.ncbi.nlm.nih.gov/pubmed/16622479
  4. Reichert JM (2008) Monoclonal antibodies as innovative therapeutics. Curr Pharm Biotechnol. 9(6): 423-30. http://www.ncbi.nlm.nih.gov/pubmed/19075682
  5. Nelson AL, Dhimolea E, Reichert JM (2010) Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov 9(10): 767-74 http://www.ncbi.nlm.nih.gov/pubmed/20811384
  6. Beerli RR, Rader C (2010). Mining human antibody repertoires. MAbs (4): 365-378. http://www.ncbi.nlm.nih.gov/pubmed/20505349
  7. Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, Panoskaltsis N (2006) Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med. 355 (10): 1018-28. http://www.ncbi.nlm.nih.gov/pubmed/16908486
  8. Weiner LM, Murray JC, Shuptrine CW. Cell (2012) Antibody-based immunotherapy of cancer. 148(6):1081-4. http://www.ncbi.nlm.nih.gov/pubmed/22424219
  9. Reichert JM, Dhimolea E (2012). The future of antibodies as cancer drugs. Drug Discov Today. 17(17-18): 954-63. http://www.ncbi.nlm.nih.gov/pubmed/22561895
  10. Chan AC, Carter PJ (2010) Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol 10: 301–16. http://www.ncbi.nlm.nih.gov/pubmed/20414204
  11. Beck A, Wurch T, Bailly C, Corvaia N (2010). Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol. 10(5):345-52. http://www.ncbi.nlm.nih.gov/pubmed/20414207

Veebiallikad:

  1. Eesti ravimiregister: http://193.40.10.165/register/register.php?keel=est&inim_vet=inim
  2. US Food and Drug Administration: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm
  3. European medicines agency: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar_search.jsp&mid=WC0b01ac058001d124
  4. mAbs, Janice M Reichert: http://www.landesbioscience.com/journals/mabs/about/ 
Eelmine